<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18439">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02069210</url>
  </required_header>
  <id_info>
    <org_study_id>SI 1</org_study_id>
    <nct_id>NCT02069210</nct_id>
  </id_info>
  <brief_title>The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients</brief_title>
  <official_title>The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wolf-Schleinzer-Stiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of transfusion of allogeneic
      (homologous) red cells on the immunologic parameters such as T-cells as well as natural
      killer cell count/function, various interleukins, TNF alpha and other immunologic relevant
      parameters on postoperative day 1,3 and 5-7 in patients undergoing spine surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Immunologic parameters</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood level of the following parameters on preoperative, postoperative day 1, 3, 5-7.
IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, Il-7, IL-8, Il-9, Il-10, Il-12, Il-13, IL-15, Il-17,basic FGF (Fibroblast growth factors).
Cell Analytics  - (mononuclear) T-Cells incl. killer cells, CD2, CD3, CD4,  CD8, CD25, CD30, CD19, CD20, CD138, CD56, CD56, CD303, CD304, NK cytotoxicity (non-radioisotope), CTL cytotoxicity (non-radioisotope), T cell proliferation, B cell, T cell.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of red cell transfusion on clinical relevant outcome parameters, such as myocardial infarction, infection rate, and length of hospital stay.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Infection After Transfusion</condition>
  <arm_group>
    <arm_group_label>Blood transfusion</arm_group_label>
    <description>Patients receive blood transfusion during operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood transfusion</intervention_name>
    <description>Intraoperative blood transfusion</description>
    <arm_group_label>Blood transfusion</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients underwent elective spine surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 - &lt; 60 years

          -  Patients underwent elective spine surgery

          -  ASA classification 1-3

        Exclusion Criteria:

          -  Patients who have the concomitant condition

          -  Cancer

          -  History of heart disease including, heart failure, coronary artery disease,
             hypertension treated with more than one medicament.

          -  Serum creatinine &gt; 1.5 mg/dL

          -  Stroke, neurologic and mental deficits, epilepsy

          -  General or local infection (site of surgery),

          -  Coagulation disorders.

          -  Intraoperative massive bleeding

          -  Infection of the spine

          -  Rheumatoid arthritis

          -  Patients who had either of the following drug (aspirin, methotrexate,  cyclosporine,
             qualaquin)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sirilak Suksompong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Faculty of medicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sirilak Suksompong, MD</last_name>
    <phone>66891534806</phone>
    <email>sirilak.suk@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sirilak Suksompong</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sirilak Suksompong, MD</last_name>
      <phone>66891534806</phone>
      <email>sirilak.suk@mahidol.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>February 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Sirilak Suksompong</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
